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Introduction
Epithelial Ovarian Cancer (EOC) represents the 
seventh most common cancer in women worldwide and is 
one of the most aggressive gynaecologic malignancy, with 
a poor prognosis in advanced stage (Haruta  et al., 2011). 
However, because there is no effective screening test for 
this tumor and its symptoms are vague, approximately 
70–80% of patients are diagnosed at advanced stage 
of the disease (stage III and IV, in accordance with the 
International Federation of Gynecology and Obstetrics 
(FIGO)) and the survival rate is low. Despite continuing 
advances in surgical and oncological therapies, EOC 
has a high probability to relapse and to develop distant 
metastases (Jaison et al., 2012). Actually, more than 70% 
of stage III–IV patients have a relapse of the disease, and 
even in stage I or II, the relapse rate is 20–25% (30–75%). 
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Galectin-3 (Gal-3) is an endogenous β-galactoside-binding lectin, playing an important role in the pathogenesis 
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The poor prognosis and the frequent disease relapses 
requires to establish periodic surveillance programs, in 
order to promptly introduce further therapeutic approaches 
thus reducing the morbidity and mortality rate.
Several studies have been conducted to assess factors 
involved in ovarian carcinogenesis, especially aimed 
to identify possible therapeutic targets and potential 
biological markers to be used as early prognostic 
indicators of disease relapse, improving the follow-up 
surveillance (Tagawa et al., 2012; Dutta et al., 2010; 
Moore  et al., 2010, Papa et al., 2016). 
Recently, it has been a great interest on a group of 
carbohydrate-binding proteins involved in tumor genesis 
and disease progression: Galectins. Galectins are a family 
of proteins playing different roles in various biological 
process. To date, fifteen members of the galectin family 
have been identified and classified into three subgroups, 
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based on their structure and numbers of the carbohydrate 
recognition-binding domain (CRD): prototype, chimera 
type and tandem repeat type (Barondes et al., 1994). 
Gal-3 is unique among the galectins in possessing a long 
proline- and glycine-rich NH2-terminal domain in addition 
to the CRD (More et al., 2016). Previous studies have 
shown a correlation between high expression of Gal-3 in 
tumor cells and the malignant properties of several types 
of cancer (Iurisci et al., 2000; Ahmed et al., 2015; Cardoso 
et al., 2016; Danguy et al., 2002; Fukumori et al., 2007). 
Gal-3 has different functions, depending on the site 
of its expression. Overexpression of intracellular Gal-3 
inhibits apoptosis while extracellular Gal-3 enhances 
tumor cell adhesion to extracellular matrix (ECM) and 
promotes the escape of tumor cells from the primary 
tumor sites leading to cancer progression (Danguy et al., 
2002). Previous investigations suggested the role of Gal-3 
in EOC carcinogenesis (Lu et al., 2016; Mirandola et al., 
2014; Kim et al., 2011) but to our knowledge no study 
has been yet conducted to evaluate its role as a marker of 
disease progression in patients with EOC. 
There is still no consensus in literature regarding 
how to best follow up women with EOC cancers. 
Currently, multi- detector contrast enhanced computed 
tomography (MDCT) performed after the administration 
of intravenous contrast medium, is the imaging modality 
of choice for staging ovarian cancer but also for treatment 
follow-up, ensuring reproducibility of the results for future 
comparison in a short examination time with a reported 
accuracy of about  92%-97% (Fischerova et al., 2014; 
Bharwani et al., 2011).
Purpose of this study is to assess the role of Gal-3 
combined with MDCT as early prognostic indicator of 
disease progression in a group of follow-up patients treated 
for ovarian cancer.
Materials and Methods
Patients 
Seventeen  follow-up patients  with recurrent ovarian 
cancer (the average time to relapse was 9 months) and 
13 follow-up patients with stable disease (median age of 
64 y, age range: 35 –82 years) diagnosed and referred to 
the Department of Radiological and Oncological Sciences 
of Policlinico Umberto I Hospital, Rome, Italy, between 
December 2012 and December 2015 were consecutively 
enrolled in the study.
At the baseline the mean value of CA125 was 382 
U/mL for patients with recurrent ovarian cancer and 20 
U/mL for patients with stable disease. Of the total 30 
women, 24 were in a postmenopausal state and 6 patients 
were in a premenopausal state. Twenty-four out of the 30 
(80%) women were affected by papillary serous carcinoma 
and 6 out of 30 (20%) were affected by papillary serous 
carcinoma ‘poorly’ differentiated and undifferentiated of 
grade G3/4. 
We selected patients at the 12-13 months of follow-up 
after cytoreductive treatment (surgery and chemotherapy) 
for EOC who performed a MDCT examination body scan 
and were then subjected to blood sampling for analysis of 
Gal-3 levels. The median interval elapsed between MDCT 
examination and blood sample was 5 days.  
All patients had histological diagnosis of EOC 
confirmed and defined on the surgical specimen obtained 
after surgery according to the International Federation of 
Gynecology and Obstetrics (new revised FIGO, 2014) 
(Prat 2014; Pereira et al., 2015)
In addition 20 healthy women  (mean age of 
60-years,age range :22- 80 years) with  no personal /family 
history of EOC and negative trans-vaginal US examination 
were included in the analysis.
Informed consent was obtained from each patient to 
participate in the study. 
Methods
Gal-3 assay
Patient sera were acquired following a standard 
collection protocol. Samples were obtained by venous 
puncture, collected in a Red Top Vacutainer, centrifuged 
for 10 min at 1,300 × g. and stored at -80 °C until analysis. 
We used BMG Gale-3 Assay, an in vitro diagnostic device 
that quantitatively measures Gal -3 in serum or plasma 
by enzyme linked immunoassorbent assay (ELISA) on a 
microtiter plate form. 
MDCT imaging protocol
All patients performed a contrast-enhanced 
high-resolution multi-detector row computed tomography 
(MDCT) (Somatom Sensation 64; Siemens Medical 
System, Erlangen, Germany) by using the following 
parameters: 0.6×64-mm2 collimation, 3-mm section 
thick-ness, 250 effective mA s, 120 kVp, and 0.8-1.5-mm 
reconstruction interval of coronal and sagittal images. 
An intravenous injection of 20 mg of butylscopolamine 
(Buscopan, Boehringer) was administered in all patients 
to relax the bowel wall and reduce peristaltic bowel 
movement before MDCT examinations. 
In MDCT bowel opacification is crucial for the 
differentiation of bowel loops from peritoneal implants 
and facilitates lymph node detection. For this purpose at 
least 1,000 ml of water was administered orally within 
1 h prior to the MDCT study. The MDCT scans were 
acquired in basal conditions and after administration of 
contrast medium, cranio-caudally, from the dome of the 
diaphragm to the pelvis. The images were post- processed 
with Multiplanar Reconstruction (MPR) on sagittal and 
coronal plane sections with a 1-mm interval to improve 
the anatomical analysis, particularly of the surface lesions. 
A dual-phase protocol, arterial and venous phases, after 
intravenous administration of contrast medium was 
performed in order to assess local tumor extent. Non-ionic 
iodinated contrast medium (350 mg I/mL, Iomeron, 
Bracco, Milan, Italy) was administered intravenously 
utilizing an automatic injector (Stellant DCT, Medrad, 
Indianola, PA) at a rate of infusion of 3- 3.5 mL/s for a 
total volume of 90- 120 mL.
Imaging Analysis
Two radiologists with 7 and 20 years of experience in 
genitourinary imaging retrospectively analyzed the MDCT 
images in consensus, blinded to patients clinical status and 
to the Gal-3 blood levels.
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threshold values of Gal- 3 identified by ROC curve 
analysis, related with the disease recurrence. Considering 
lymphoadenopathies the cut-off value was 92.45 ng/ml 
(AUC :0.81,CI:0.67-0.97, Se=91% Spe=73%) while  for 
metastasis was 99.05ng/ml (AUC :0,78, CI:0.60-0.94 
Se=100% , Spe=70%) (Figure 2).
Considering local tumor spread and carcinomatosis 
values identified by ROC curves were respectively  99.05 
(AUC:0.90 ,CI:076-1.02, Se=100% , Spe=73% ) and 85.95 
ng/ml (AUC :0.93,CI:0.80-1.06, Se = 93.7%, Sp=92.8%) 
(Figure 3).
The different MDCT signs of disease relapse in patient 
with recurrent disease are shown in Table1.
Elevated serum Gal-3 levels were significantly 
correlated with imaging findings of disease recurrence 
and particularly with the presence of local recurrence 
(n=11/17, p:0.001), carcinomatosis (n=16/17, p:0.00), 
lymphoadenopathies (n=15/17, p:0.00) and distant 
The following imaging findings considered as signs 
of disease activity were recorded:
a) Local tumor recurrence: including the presence of 
solid tissue near the vaginal vault,  the parametria, the 
bladder, the ureters, bowel or pelvic side-wall invasion.
b) Peritoneal carcinomatosis: single or multiple sites of 
micro-nodular implants (<1 cm) or diffuse macronodular 
implants (1.5 cm) above or below the mesocolon and 
omental involvement with marked thickening (omental 
cake).
c) Lymphoadenophaties: The onset of lymph node >1 
cm and/or the 20 % size increase of pre-existing lymph 
nodes. 
d) Distant Metastasis. 
e) Presence/Absence of ascites.
Stable ovarian cancer was diagnosed when the disease 
did not follow any of the parameters described above.
Statistical evaluation
The ROC analysis was used to assess the different 
cut-off values of Gal-3 for each imaging findings of 
disease relapse. Results were presented with 95% of 
Confidence Intervals (CI 95%).
We performed the Fisher’s exact probability test for 
univariate analyses and, where possible, the χ2 test with 
continuity correction to assess the statistical significance 
of difference in Gal-3 levels and MDCT imaging findings 
between patients affected by recurrent disease and patients 
with stable disease.
Statistical analysis was performed using SPSS 19.0 
for Windows®. Statistical significance was set at p<0.05.
Results
The mean serum levels of Gal-3 were 29.8 ng/ ml in 
healthy controls (range:14- 75 ng/dl),  22.2 ng/ml (range 
:18.5- 28 ng/dl) in patients with stable disease and 103.2 
ng/ml (82- 150 ng /dl)  in patients with recurrent disease.
Serum levels of Gal-3 in patients with disease 
progression were significantly higher than those in stable 
disease patients (p<0.001) and those in healthy controls 
(P: 0.004), but no differences were found between stable 
disease patients and healthy controls (p:0.7).The Gal-3 
values distribution of follow-up patients is shown in 
Figure 1.
For each imaging findings we calculated the respective 
A LTS C L M
1 + + + + +
2 + + + + +
3 + + + + +
4 + + + + +
5 – + – + +
6 – + + + +
7 + – + + –
8 – + + – –
9 + + + + +
10 – + + + +
11 + – + + –
12 + – + + –
13 + + + – +
14 – – + + –
15 – + + + +
16 + – + + –
17 + – + + +
Table 1. Imaging Findings in Patients with Disease 
Relapse 
A, Ascites ; LTS, Local Tumor Spread; C, Carcinomatosis; L, 
Lymphoadenopathyes; M, Metastasis)
Figure 1. Frequency Distribution of Gal 3 Values in 
Patients with Stable Disease and in Those with Disease 
Progression
Figure 2. ROC Curve Analysis for Determining the 
Threshold Value of Gal-3 for Lymphoadenopathies 
( 92.45 ng/ml, AUC :0.81, CI:0.67-0.97 ) and for 
Metastasis (99.05ng/ml, AUC :0,78, CI:0.60-0.94)
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metastasis (n=11/17, p:0.003) . 
Considering distant metastasis the most frequente site 
was liver (n=5), followed by lung (n=4) and pleura (n=2)
However we found that Gal-3 expression was not 
related to Patients age (p: 0.4)  and with the presence of 
ascites (p:0.006).
Discussion 
Gal-3, a beta-galactoside-binding lectin, is a member 
of the galectin family implicated in several biological 
events (Wang et al., 2016). A series of experimental 
evidences assessed the role of Gal-3 expressions in 
tumorigenesis. Indeed, extracellular Gal-3 seems to be 
associated with cell migration, adhesion, and cellular 
interactions while intracellular Gal-3 inhibits apoptosis 
and is highly related in neoplastic progression and 
metastasis spreading (Yoshii et al., 2016; Newlaczyl et 
al ., 2011; Liu et al ., 2005).
The functional significance of Gal-3 overexpression in 
EOC is not yet well known. The most important biological 
characteristics of EOC include tumor infiltration into the 
surrounding tissues and the implantation of metastasis. 
At the time of diagnosis, most (75%) epithelial ovarian 
cancers have progressed to stage III or IV and the majority 
of patients with advanced or high-grade ovarian cancer 
relapse and die of disease ( Armstrong et al ., 2002; Herzog 
et al., 2004).  For that reason great attention has been paid 
to find biological markers to be used as early predictor of 
disease relapse (Rossi et al., 2016; Musella et al., 2017; 
Marchetti et al., 2014).
In the last few years, the combination of biomarkers 
has been utilized to improve specificity in advanced 
ovarian cancer. Currently the biological markers accepted 
and used in the detection of disease recurrence and lymph 
node dissemination are   Ca125 and  HE4 (Freydank et al., 
2012; Zhen et al ., 2014;Anastasi et al ., 2014; Manganaro 
et al ., 2013; Midulla et al ., 2012).
Previous studies have suggested that Gal-3 can be 
used as disease marker in ovarian cancer diagnosis. 
Gal-3 seems to mediate drug resistance, promote 
motility and  metastatic invasion thus supporting the 
importance of Gal-3 as a potential therapeutic target in 
EOC. Balasubramanian et al., (2009) examined urinary 
Gal-3 levels to stage ovarian cancer and found a strong 
correlation between the stage of disease at diagnosis with 
Gal-3 concentrations. Kim et al., (2011) in their series, 
showed that high Gal-3 expression in EOC correlated with 
shorter progression-free survival of patients .
To the best of our knowledge this study is the first 
one evaluating the role of Gal-3 combined with MDCT 
as a potential prognostic factor in predicting disease 
recurrence.
We found that Gal-3 protein expression in patients 
with recurrent disease was significantly up-regulated 
compared to patients with stable disease (p<0.001) and 
those in healthy controls (p< 0.004). 
The most innovative aspect of our study was to assess 
the combination of  Gal-3 with the different signs of 
disease relapse on MDTC which is the standard imaging 
method for the post- operative surveillance of women 
with ovarian cancer according the European Society 
of Urogenital Radiology and the American College of 
Radiology guidelines for ovarian cancer staging and 
follow up (Forstener et al ., 2010; Mitchell et al., 2013). 
Multi-detector contrast-enhanced Computed Tomography 
is an available and accurate imaging method that allows 
a proper assessment of the disease extension in a short 
examination time. Recurrent ovarian malignancy usually 
appears as a pelvic mass at the site of surgery or as diffuse 
peritoneal carcinomatosis, pleuro-pulmonary lesions, 
lymph node, or liver metastases (Diaz-Gil et al., 2016). 
We found a statistic correlation between high levels 
of Gal-3 and presence of lymphoadenopaties (p<0.001). 
No previous studies related metastatic lymph-nodes in 
EOC with the circulating levels of Gal-3.
However Miyazaki et al showed that  Gal-3 expression 
was observed significantly stronger in metastatic lymph 
nodes than in the primary gastric cancers (Miyazaki et al., 
2002) , while  Salajegheh et al found that overexpression 
of galectin-1 and 3 proteins were higher in patients with 
papillary thyroid carcinoma with lymph node metastases 
( Salajegheh et al ., 2014).
In addition we found a strong correlation between 
high levels of Gal- 3 in patients presenting local tumor 
recurrence (p<0.001) and metastasis (p<0.003) 
This is probably related to the enhanced cell adhesion 
to extracellular matrix components, cell motility and 
invasiveness due to Gal-3 over-expression, activating 
molecules related to the adhesion of ovarian cancer cells, 
such as β1 integrins and E-cadherin. This results are in 
agreement with a previous study of Lu H et al., (2016)
demonstrating  that Galectin-3 regulates metastatic 
capabilities and chemotherapy sensitivity in epithelial 
ovarian carcinoma via NF-κB pathway. This could 
have important implications also in the therapeutic 
management of EOC. Mirandola et al., (2014) suggested 
that the Gal-3 inhibitor could inhibit the invasive and 
migratory capabilities of ovarian cancer cell lines and 
primary cancer cells.
Finally in our study we found higher levels of  Gal 3 
levels in  patients with carcinomatosis (p<0.00) compared 
to the healthy controls. Carcinomatosis is often the most 
common manifestation of disease recurrence in EOC 
Figure 3. ROC Curve Analysis for Determining the 
Threshold Value of Gal-3 for Local Tumor Spread 
(99.05, AUC:0.90, CI:076-1.02) and Carcinomatosis 
(85.95 ng/ml, AUC :0.93, CI:0.80-1,06).
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patients. Yang et al., (2006) found that the expression of 
Gal- 3 in gastric cancer lesions can be used as a biological 
marker of peritoneal metastasis from gastric cancer.
In our study we used MDCT to detect recurrence of 
disease. The choice of using MDCT examination is due to 
its availability, to low radiation dose in comparison with 
Computed Tomography- Positron Emission Tomography 
(CT-PET) and to the costs. Several studies validated the 
effectiveness of Fluorodeoxyglucose (FDG) CT-PET in 
the assessment of patients with recurrent ovarian cancer 
(Brunetti et al., 2006; Grant et al ., 2014). Actually FDG 
CT-PET has a reported sensitivity of 80%- 100% for the 
detection of recurrent ovarian cancer, But a critical factor 
is represented by its spatial resolution (approximately 
6-10 mm); therefore, its sensitivity for depicting lesions 
smaller than 1 cm is lower than that for larger lesions. 
Sub-centimeter lesions of omental carcinomatosis may 
not demonstrate sufficient radiotracer uptake, even if 
infiltrative changes indicative of the presence of disease 
are seen at MDCT. 
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